Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Soft tissue sarcoma, adult
Stage/Subtype:  recurrent adult soft tissue sarcoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 51 for your search:
Start Over
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
Phase: Phase III
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ALDOXORUBICIN-P3-STS-01, NCT02049905
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AVF4761s, 200911736, NCT01106872
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
Aerosol IL-2 for Pulmonary Metastases
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Other
Protocol IDs: 2010-0700, NCI-2012-00788, NCT01590069
Proton or Photon RT for Retroperitoneal Sarcomas
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 12-100, NCT01659203
A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 105SAR101, NCT01975519
A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SARC023, NCT02008877
Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 13 moths to 29 years
Sponsor: NCI, Other
Protocol IDs: 2013-171, NCI-2014-01149, P30CA022453, NCT02173093
PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 30
Sponsor: NCI
Protocol IDs: 150093, 15-C-0093, NCT02390752
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, Other, NCT00592293
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 090192, 09-C-0192, NCT00942877
Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: 7943, NCI-2012-00052, IRB# 7943, NCT01532687
A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: MUSC 101644, PAZ115785, NCT01593748
Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SARC016, NCT01661283
Cabozantinib for Adults With Advanced Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130044, 13-C-0044, NCT01755195
A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 40
Sponsor: Other
Protocol IDs: J12106, NCT01804634
Definitive Therapy for Oligometastatic Solid Malignancies
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Carter 2005-01, 1073869, NCT01898962
Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 201309108, NCT01986829
A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SARC024, NCT02048371
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NU 13S02, NCI-2013-02278, STU00087654, ONC-2013-129, P30CA060553, NCT02048722
A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Other
Protocol IDs: SARC028, NCT02301039
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NU 14S03, NCI-2014-02583, STU00200112, P30CA060553, NCT02357810
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
Phase: Phase II
Type: Treatment
Status: Active
Age: 14 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: ONC2014-001, 1R44CA183075-01A1, NCT02423863
Start Over